The 24-week mark represented the midpoint, with average losses reaching 17% and significant improvements in waist measurements, blood pressure, and metabolic markers
Prepare for assistance at home, set attainable goals, and have consistent check-ins
Using unproven GLP-1 patches carries several significant risks beyond simple ineffectiveness
While dedicated large-scale trials in post-bariatric populations are ongoing, retrospective studies suggest efficacy in patients with weight regain
Among the GLP-1 analogs, tirzepatide showed the most pronounced decrease in respiratory quotient (RQ) (Fig
The most commonly reported side effects include gastrointestinal issues such as nausea, vomiting, diarrhea, abdominal pain, and constipation